New hormonal agent may slow progression of early-stage prostate cancer during active surveillance


For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in the Journal of Urology.

Study identifies neuronal basis of impaired consciousness in ‘absence’ epilepsy

Previous article

Anticancer drugs: A new hope for sepsis treatment

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations